Ad is loading...
CPRX
Price
$20.60
Change
-$1.09 (-5.03%)
Updated
Nov 15 closing price
115 days until earnings call
MNKD
Price
$6.80
Change
-$0.22 (-3.13%)
Updated
Nov 15 closing price
107 days until earnings call
Ad is loading...

CPRX vs MNKD

Header iconCPRX vs MNKD Comparison
Open Charts CPRX vs MNKDBanner chart's image
Catalyst Pharmaceuticals
Price$20.60
Change-$1.09 (-5.03%)
Volume$1.71M
CapitalizationN/A
MannKind
Price$6.80
Change-$0.22 (-3.13%)
Volume$5.22M
CapitalizationN/A
CPRX vs MNKD Comparison Chart
Loading...
CPRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CPRX vs. MNKD commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPRX is a Sell and MNKD is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (CPRX: $20.60 vs. MNKD: $6.80)
Brand notoriety: CPRX and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CPRX: 173% vs. MNKD: 226%
Market capitalization -- CPRX: $2.46B vs. MNKD: $1.88B
CPRX [@Biotechnology] is valued at $2.46B. MNKD’s [@Biotechnology] market capitalization is $1.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPRX’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 1 green FA rating(s).

  • CPRX’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 1 green, 4 red.
According to our system of comparison, CPRX is a better buy in the long-term than MNKD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPRX’s TA Score shows that 3 TA indicator(s) are bullish while MNKD’s TA Score has 2 bullish TA indicator(s).

  • CPRX’s TA Score: 3 bullish, 6 bearish.
  • MNKD’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, CPRX is a better buy in the short-term than MNKD.

Price Growth

CPRX (@Biotechnology) experienced а -13.92% price change this week, while MNKD (@Biotechnology) price change was -7.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

CPRX is expected to report earnings on Mar 12, 2025.

MNKD is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CPRX($2.46B) has a higher market cap than MNKD($1.88B). MNKD has higher P/E ratio than CPRX: MNKD (85.00) vs CPRX (17.46). MNKD YTD gains are higher at: 86.813 vs. CPRX (22.546). CPRX has higher annual earnings (EBITDA): 122M vs. MNKD (53.3M). CPRX has more cash in the bank: 376M vs. MNKD (248M). CPRX has less debt than MNKD: CPRX (3.38M) vs MNKD (231M). CPRX has higher revenues than MNKD: CPRX (434M) vs MNKD (248M).
CPRXMNKDCPRX / MNKD
Capitalization2.46B1.88B131%
EBITDA122M53.3M229%
Gain YTD22.54686.81326%
P/E Ratio17.4685.0021%
Revenue434M248M175%
Total Cash376M248M152%
Total Debt3.38M231M1%
FUNDAMENTALS RATINGS
CPRX vs MNKD: Fundamental Ratings
CPRX
MNKD
OUTLOOK RATING
1..100
8482
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
1919
SMR RATING
1..100
59100
PRICE GROWTH RATING
1..100
4538
P/E GROWTH RATING
1..100
8884
SEASONALITY SCORE
1..100
5028

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPRX's Valuation (64) in the Pharmaceuticals Other industry is in the same range as MNKD (76) in the Biotechnology industry. This means that CPRX’s stock grew similarly to MNKD’s over the last 12 months.

CPRX's Profit vs Risk Rating (19) in the Pharmaceuticals Other industry is in the same range as MNKD (19) in the Biotechnology industry. This means that CPRX’s stock grew similarly to MNKD’s over the last 12 months.

CPRX's SMR Rating (59) in the Pharmaceuticals Other industry is somewhat better than the same rating for MNKD (100) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than MNKD’s over the last 12 months.

MNKD's Price Growth Rating (38) in the Biotechnology industry is in the same range as CPRX (45) in the Pharmaceuticals Other industry. This means that MNKD’s stock grew similarly to CPRX’s over the last 12 months.

MNKD's P/E Growth Rating (84) in the Biotechnology industry is in the same range as CPRX (88) in the Pharmaceuticals Other industry. This means that MNKD’s stock grew similarly to CPRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPRXMNKD
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
68%
Momentum
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
77%
MACD
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 12 days ago
87%
Declines
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 5 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
74%
Aroon
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Ad is loading...
CPRX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEIGX52.92-0.21
-0.40%
MFS Value R1
RLAIX19.38-0.11
-0.56%
T. Rowe Price Latin America I
MSEIX67.74-0.60
-0.88%
AMG Veritas Asia Pacific I
HFDCX19.68-0.25
-1.25%
Hartford Schroders US MidCap Opps C
LMPMX39.67-0.69
-1.71%
ClearBridge Small Cap Growth 1

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with MGTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
-5.03%
MGTX - CPRX
45%
Loosely correlated
-2.41%
MNKD - CPRX
40%
Loosely correlated
-3.13%
BCRX - CPRX
39%
Loosely correlated
-5.64%
EXAI - CPRX
39%
Loosely correlated
-11.68%
VCEL - CPRX
38%
Loosely correlated
-0.49%
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with QSI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then QSI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
-3.13%
QSI - MNKD
44%
Loosely correlated
-5.77%
NTLA - MNKD
44%
Loosely correlated
-7.61%
VCYT - MNKD
44%
Loosely correlated
-2.97%
BEAM - MNKD
43%
Loosely correlated
-8.59%
PGEN - MNKD
42%
Loosely correlated
-7.11%
More